• Je něco špatně v tomto záznamu ?

Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience

M. Ondrusova, I. Waczulikova, V. Lehotska, T. Zeleny, D. Ondrus,

. 2017 ; 15 (6) : e1015-e1019. [pub] 20170601

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010435

BACKGROUND: Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). PATIENTS AND METHODS: From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients). Differences between relapse rates and overall survival rates in these groups were statistically analyzed. RESULTS: In the AS group, relapse occurred in 52 (17.3%) of 301 patients with a median follow-up of 7.2 months (range, 2-86 months). Six (2.0%) patients of this group died, with a median follow-up of 34.3 months (range, 11-102 months). In the ACT group, relapse occurred in 2 (1.1%) of 184 patients with a median follow-up of 56.2 months (range, 42-70 months). One (0.54%) patient died at 139.4 months following orchiectomy. The relapse rate for the AS group was 16.7 times higher than that for the ACT group. The groups did not differ in overall survival. The 3-year overall survival of all patients with CSI NSGCTT was 99.1% (95% confidence interval, 97.7%-99.7%). Three of a total of 7 deaths occurred thereafter. CONCLUSIONS: The policy of AS is recommended only in patients with low-risk CSI NSGCTT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010435
003      
CZ-PrNML
005      
20200715101030.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clgc.2017.05.023 $2 doi
035    __
$a (PubMed)28673797
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ondrusova, Martina $u St Elizabeth University of Health and Social Sciences, Bratislava, Slovak Republic; Department of Epidemiology and Biostatistics, Pharm-In, Ltd, Bratislava, Slovak Republic.
245    10
$a Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Tumors: A 25-year Single-center Experience / $c M. Ondrusova, I. Waczulikova, V. Lehotska, T. Zeleny, D. Ondrus,
520    9_
$a BACKGROUND: Surveillance after orchiectomy alone has become popular in the management of clinical stage I nonseminomatous germ cell testicular tumors (CSI NSGCTT). Efforts to identify patients at high risk of disease progression led to a search for risk factors in CSI NSGCTT. The aim of this study was to analyze a 25-year single-center experience with risk-adapted therapeutic approaches-active surveillance (AS) versus adjuvant chemotherapy (ACT). PATIENTS AND METHODS: From January 1992 to January 2017, a total of 485 patients with CSI NSGCTT were stratified into the AS group (low-risk patients) and the ACT group (high-risk patients). Differences between relapse rates and overall survival rates in these groups were statistically analyzed. RESULTS: In the AS group, relapse occurred in 52 (17.3%) of 301 patients with a median follow-up of 7.2 months (range, 2-86 months). Six (2.0%) patients of this group died, with a median follow-up of 34.3 months (range, 11-102 months). In the ACT group, relapse occurred in 2 (1.1%) of 184 patients with a median follow-up of 56.2 months (range, 42-70 months). One (0.54%) patient died at 139.4 months following orchiectomy. The relapse rate for the AS group was 16.7 times higher than that for the ACT group. The groups did not differ in overall survival. The 3-year overall survival of all patients with CSI NSGCTT was 99.1% (95% confidence interval, 97.7%-99.7%). Three of a total of 7 deaths occurred thereafter. CONCLUSIONS: The policy of AS is recommended only in patients with low-risk CSI NSGCTT.
650    _2
$a dospělí $7 D000328
650    _2
$a adjuvantní chemoterapie $x metody $x mortalita $7 D017024
650    _2
$a management nemoci $7 D019468
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a staging nádorů $7 D009367
650    _2
$a germinální a embryonální nádory $x farmakoterapie $x mortalita $x chirurgie $7 D009373
650    _2
$a recidiva $7 D012008
650    _2
$a analýza přežití $7 D016019
650    _2
$a testikulární nádory $x farmakoterapie $x mortalita $x chirurgie $7 D013736
650    _2
$a výsledek terapie $7 D016896
650    _2
$a pozorné vyčkávání $x metody $7 D057832
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Waczulikova, Iveta $u Department of Nuclear Physics and Biophysics, Faculty of Mathematics, Physics, and Informatics, Comenius University, Bratislava, Slovak Republic.
700    1_
$a Lehotska, Viera $u Second Department of Radiology, Faculty of Medicine, Comenius University, St Elisabeth Cancer Institute, Bratislava, Slovak Republic.
700    1_
$a Zeleny, Tomas $u Institute for Hygiene and Epidemiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Ondruš, Dalibor, $d 1953- $u First Department of Oncology, Faculty of Medicine, Comenius University, St Elisabeth Cancer Institute, Bratislava, Slovak Republic. Electronic address: dalibor.ondrus@ousa.sk. $7 xx0051658
773    0_
$w MED00188741 $t Clinical genitourinary cancer $x 1938-0682 $g Roč. 15, č. 6 (2017), s. e1015-e1019
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28673797 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20200715101026 $b ABA008
999    __
$a ok $b bmc $g 1287920 $s 1007247
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 15 $c 6 $d e1015-e1019 $e 20170601 $i 1938-0682 $m Clinical genitourinary cancer $n Clin Genitourin Cancer $x MED00188741
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace